Our Pipeline
Harnessing the therapeutic power of cannabinoids
We are developing a portfolio of prescription medicines that harness the therapeutic benefits of cannabinoids to treat people living with debilitating chronic neuropathic pain conditions that remain under-served by existing medicines.
Our approach is to make medicines that target an important biological system in the body, known as the Endocannabinoid System (ECS). The ECS plays an important role in maintaining the balance between our physical and mental health including regulating pain, mood, memory, sleep, appetite, and the immune response to cancer.
Where this balance becomes disrupted by disease, the aim is to restore it with cannabinoid-based treatments that are rigorously tested and approved by regulators such as the FDA so that they can be prescribed by physicians and reimbursed by insurers.
We are working with three types of cannabinoid compounds
Synthesized phytocannabinoids where the cannabinoid found in the plant is chemically reproduced e.g. CBD, THC
Cannabinoid derivatives where the compounds are chemically modified to improve drug-like characteristics
Novel chemical entities (NCEs) - these are not cannabinoids but are chemically synthesized to behave like them and interact with cannabinoid receptors
Currently there are four active programmes and it is expected that each medicine will serve to resolve not just one but several severe chronic conditions including some rare conditions. In addition, our library comprising over 500 proprietary cannabinoid derivatives, and 14 patent families will continue to support development of further medicines to treat unmet medical needs.
